Brookline Capital Management Comments on Eyenovia, Inc.’s FY2028 Earnings (NASDAQ:EYEN)

Eyenovia, Inc. (NASDAQ:EYEN) – Stock analysts at Brookline Capital Management cut their FY2028 earnings per share (EPS) estimates for Eyenovia in a report released on Thursday, May 16th. Brookline Capital Management analyst K. Dolliver now expects that the company will post earnings of $0.04 per share for the year, down from their prior forecast of $0.05. The consensus estimate for Eyenovia’s current full-year earnings is ($0.69) per share.

Eyenovia (NASDAQ:EYEN) last released its quarterly earnings results on Monday, March 18th. The company reported ($0.17) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.17). During the same period last year, the firm earned ($0.17) earnings per share.

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $12.00 price objective on shares of Eyenovia in a research report on Thursday.

Eyenovia Stock Performance

Shares of NASDAQ EYEN traded up $0.03 during trading on Friday, reaching $0.85. The company had a trading volume of 73,363 shares, compared to its average volume of 1,099,372. Eyenovia has a twelve month low of $0.50 and a twelve month high of $3.59. The stock has a 50-day moving average price of $0.93 and a two-hundred day moving average price of $1.42. The company has a debt-to-equity ratio of 1.00, a quick ratio of 2.16 and a current ratio of 2.17.

Institutional Investors Weigh In On Eyenovia

A number of institutional investors have recently added to or reduced their stakes in the company. Vanguard Group Inc. grew its position in Eyenovia by 25.2% during the first quarter. Vanguard Group Inc. now owns 1,790,501 shares of the company’s stock valued at $1,765,000 after acquiring an additional 360,924 shares during the period. BNP Paribas Financial Markets boosted its position in shares of Eyenovia by 1,444.4% in the first quarter. BNP Paribas Financial Markets now owns 219,610 shares of the company’s stock worth $217,000 after buying an additional 205,390 shares during the period. PFG Investments LLC purchased a new stake in shares of Eyenovia in the first quarter worth about $69,000. Leo Wealth LLC acquired a new stake in shares of Eyenovia in the fourth quarter valued at about $34,000. Finally, Armistice Capital LLC raised its holdings in shares of Eyenovia by 41.8% during the 4th quarter. Armistice Capital LLC now owns 4,378,000 shares of the company’s stock valued at $9,106,000 after buying an additional 1,290,979 shares during the period. Hedge funds and other institutional investors own 25.84% of the company’s stock.

Insider Activity

In other Eyenovia news, major shareholder Stuart M. Grant acquired 50,000 shares of the stock in a transaction dated Tuesday, March 19th. The stock was acquired at an average price of $1.23 per share, with a total value of $61,500.00. Following the completion of the transaction, the insider now directly owns 5,330,715 shares in the company, valued at $6,556,779.45. The purchase was disclosed in a document filed with the SEC, which is accessible through the SEC website. In other news, major shareholder Stuart M. Grant purchased 100,000 shares of the stock in a transaction on Thursday, March 28th. The stock was purchased at an average price of $0.98 per share, with a total value of $98,000.00. Following the completion of the transaction, the insider now owns 5,430,715 shares in the company, valued at $5,322,100.70. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, major shareholder Stuart M. Grant purchased 50,000 shares of the stock in a transaction on Tuesday, March 19th. The shares were purchased at an average cost of $1.23 per share, with a total value of $61,500.00. Following the transaction, the insider now owns 5,330,715 shares of the company’s stock, valued at approximately $6,556,779.45. The disclosure for this purchase can be found here. Insiders acquired a total of 160,717 shares of company stock valued at $176,433 over the last quarter. Company insiders own 7.10% of the company’s stock.

Eyenovia Company Profile

Eyenovia, Inc, an ophthalmic technology company, engages in the development of therapeutics based on its proprietary microdose array print platform technology. The company's product candidates include MicroPine, which is in Phase III clinical development program with indications for pediatric myopia progression (near-sightedness); MicroLine, which is in Phase III clinical development program with indications for the improvement in near vision in people with presbyopia; and Mydcombi, which is in Phase III clinical development program with indications for pharmaceutical mydriasis.